xanomeline has been researched along with Psychoses in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, MB; Bymaster, F; Fink-Jensen, A; Gerlach, J; Lundbaek, JA; Peacock, L; Werge, T | 1 |
| Bymaster, FP; Fink-Jensen, A; Hart, JC; Jeppesen, L; Peters, SC; Rasmussen, K; Sauerberg, P; Shannon, HE; Sheardown, MJ; Swedberg, MD | 1 |
2 other study(ies) available for xanomeline and Psychoses
| Article | Year |
|---|---|
The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Cebus; Male; Muscarinic Agonists; Psychotic Disorders; Pyridines; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Receptors, Muscarinic; Thiadiazoles | 2003 |
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Brain; Cholinergic Agonists; Conditioning, Psychological; Disease Models, Animal; Dopamine; Electrophysiology; Male; Mice; Mice, Inbred Strains; Muscarinic Agonists; Neurons; Psychotic Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Schizophrenia; Thiadiazoles | 2000 |